Latest Content

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure and waist size.

Health systems are using pharmacist-run titration clinics, auto-consult triggers, and discharge follow-up to close gaps in HFpEF and HFmrEF care.

Health care special purpose acquisition companies in 2020-2021 represented a temporary market inefficiency that enabled weaker companies to bypass traditional due diligence and ultimately led to failures.

Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.

Machine learning prediction of procalcitonin positivity using inexpensive routine laboratory tests may reduce procalcitonin test volume and support diagnostic stewardship.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when the disease relapsed as AML.